Kairos Pharma, Ltd.
KAPA
$0.9074
-$0.077-7.82%
AMEX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.73M | 1.62M | 1.63M | 1.63M | 682.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.98M | 1.89M | 1.88M | 1.71M | 805.00K |
| Operating Income | -1.98M | -1.89M | -1.88M | -1.71M | -805.00K |
| Income Before Tax | -2.74M | -2.01M | -1.99M | -1.81M | -890.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.74 | -2.01 | -1.99 | -1.81 | -0.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.74M | -2.01M | -1.99M | -1.81M | -890.00K |
| EBIT | -1.98M | -1.89M | -1.88M | -1.71M | -805.00K |
| EBITDA | -1.82M | -1.73M | -1.72M | -1.55M | -645.00K |
| EPS Basic | -0.26 | -0.19 | -0.19 | -0.17 | -0.09 |
| Normalized Basic EPS | -0.16 | -0.12 | -0.12 | -0.11 | -0.05 |
| EPS Diluted | -0.26 | -0.19 | -0.19 | -0.17 | -0.09 |
| Normalized Diluted EPS | -0.16 | -0.12 | -0.12 | -0.11 | -0.05 |
| Average Basic Shares Outstanding | 42.56M | 41.99M | 41.76M | 41.53M | 41.34M |
| Average Diluted Shares Outstanding | 42.56M | 41.99M | 41.76M | 41.53M | 41.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |